Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids.

Sarafianos SG, Das K, Clark AD Jr, Ding J, Boyer PL, Hughes SH, Arnold E.

Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10027-32.

2.

The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.

Gao HQ, Boyer PL, Sarafianos SG, Arnold E, Hughes SH.

J Mol Biol. 2000 Jul 7;300(2):403-18.

PMID:
10873473
3.
4.

Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophage.

Jamburuthugoda VK, Santos-Velazquez JM, Skasko M, Operario DJ, Purohit V, Chugh P, Szymanski EA, Wedekind JE, Bambara RA, Kim B.

J Biol Chem. 2008 Apr 4;283(14):9206-16. doi: 10.1074/jbc.M710149200. Epub 2008 Jan 24.

5.
6.
7.

A positively charged side chain at position 154 on the beta8-alphaE loop of HIV-1 RT is required for stable ternary complex formation.

Sharma B, Kaushik N, Upadhyay A, Tripathi S, Singh K, Pandey VN.

Nucleic Acids Res. 2003 Sep 1;31(17):5167-74.

10.

A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation.

Fan N, Rank KB, Slade DE, Poppe SM, Evans DB, Kopta LA, Olmsted RA, Thomas RC, Tarpley WG, Sharma SK.

Biochemistry. 1996 Jul 30;35(30):9737-45.

PMID:
8703945
11.

Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.

Liu J, Yue J, Wu S, Yan Y.

Arch Virol. 2007;152(10):1799-805. Epub 2007 Jul 6.

PMID:
17619115
12.

Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.

Feng JY, Myrick FT, Margot NA, Mulamba GB, Rimsky L, Borroto-Esoda K, Selmi B, Canard B.

Nucleosides Nucleotides Nucleic Acids. 2006;25(1):89-107.

PMID:
16440988
13.

Purifying selection masks the mutational flexibility of HIV-1 reverse transcriptase.

Smith RA, Anderson DJ, Preston BD.

J Biol Chem. 2004 Jun 18;279(25):26726-34. Epub 2004 Mar 9.

14.

Mechanistic interplay among the M184I HIV-1 reverse transcriptase mutant, the central polypurine tract, cellular dNTP concentrations and drug sensitivity.

Van Cor-Hosmer SK, Daddacha W, Kim B.

Virology. 2010 Oct 25;406(2):253-60. doi: 10.1016/j.virol.2010.07.028. Epub 2010 Aug 10.

15.

A role for dNTP binding of human immunodeficiency virus type 1 reverse transcriptase in viral mutagenesis.

Weiss KK, Chen R, Skasko M, Reynolds HM, Lee K, Bambara RA, Mansky LM, Kim B.

Biochemistry. 2004 Apr 20;43(15):4490-500.

PMID:
15078095
16.

Single Active Site Mutation Causes Serious Resistance of HIV Reverse Transcriptase to Lamivudine: Insight from Multiple Molecular Dynamics Simulations.

Moonsamy S, Bhakat S, Walker RC, Soliman ME.

Cell Biochem Biophys. 2016 Mar;74(1):35-48. doi: 10.1007/s12013-015-0709-2.

PMID:
26972300
17.

Interactions of enantiomers of 2',3'-didehydro-2',3'-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase.

Ray AS, Murakami E, Peterson CN, Shi J, Schinazi RF, Anderson KS.

Antiviral Res. 2002 Dec;56(3):189-205.

PMID:
12406504
18.
19.

Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.

Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, Techasathit W, Ubolyam S, Chuenyam T, Emery S, Cooper D, Lange J, Phanuphak P.

AIDS. 2003 Sep 5;17(13):1889-96.

PMID:
12960821
20.

Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.

Bergroth T, Ekici H, Gisslén M, Loes SK, Goh LE, Freedman A, Lampe F, Johnson MA, Sönnerborg A.

J Med Virol. 2009 Jan;81(1):1-8. doi: 10.1002/jmv.21363.

PMID:
19031460

Supplemental Content

Support Center